Lancet (London, England) · 2026
Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Joo Myung, Lee Seung Hun, Gim Dong Hyun, Lee Sang Yoon, Choi Ki Hong, Ahn Joon Ho, Hong Young Joon, Kim Hyun Kuk, Lee Kwan Yong, Choo Eun Ho, Jeon Ki-Hyun, Kim Hangyul, Kang Min Gyu, Koh Jin-Sin, Joh Hyun Sung, Park Taek Kyu, Yang Jeong Hoon, Song Young Bin, Choi Seung-Hyuk, Gwon Hyeon-Cheol, Hahn Joo-Yong, Multicenter FLOW-CMD investigators
Аннотация
BACKGROUND: Coronary microvascular dysfunction often coexists with epicardial coronary artery disease. Data regarding its prevalence and prognosis in patients undergoing invasive coronary angiography are scarce. This study aimed to evaluate the prevalence and prognosis of coronary microvascular dysfunction in patients undergoing clinically indicated invasive coronary angiography in routine practice.
METHODS: In this prospective, multicentre cohort study done in seven tertiary medical hospitals in South Korea, consecutive patients aged 18 years and older who were referred for clinically indicated invasive coronary angiography were systematically screened and evaluated by coronary physiological assessment. Obstructive epicardial coronary artery disease was defined as an intermediate stenosis (40-90% diameter stenosis), with fractional flow reserve of 0·80 or less or severe stenosis (>90% of diameter stenosis) treated with revascularisation without fractional flow reserve measurement. Coronary microvascular dysfunction was identified as coronary flow reserve below 2·0 and index of microcirculatory resistance of ≥25. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure. The Multicenter FLOW-CMD Registry study is registered with ClinicalTrials.gov (NCT05369182).
FINDINGS: Between April 22, 2022, and Nov 19, 2024, 5764 patients were screened and 1003 patients were enrolled (756 men and 247 women). Among these patients, coronary microvascular dysfunction was observed in 123 (21·5%) of 573 patients with obstructive epicardial coronary artery disease and in 40 (9·3%) of 430 patients without obstructive epicardial coronary artery disease. At a median follow-up of 1·9 years, the primary endpoint occurred in 26 patients (2-year Kaplan-Meier estimate 18·8%) with coronary microvascular dysfunction and 70 patients (2-year Kaplan-Meier estimate 10·5%) with preserved microvascular function (hazard ratio 1·91 [95% CI 1·22-2·99]; p=0·0047).
INTERPRETATION: In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction coexisted with epicardial coronary artery disease and was associated with a higher risk of the composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.
FUNDING: Abbott Vascular and Boston Scientific.
METHODS: In this prospective, multicentre cohort study done in seven tertiary medical hospitals in South Korea, consecutive patients aged 18 years and older who were referred for clinically indicated invasive coronary angiography were systematically screened and evaluated by coronary physiological assessment. Obstructive epicardial coronary artery disease was defined as an intermediate stenosis (40-90% diameter stenosis), with fractional flow reserve of 0·80 or less or severe stenosis (>90% of diameter stenosis) treated with revascularisation without fractional flow reserve measurement. Coronary microvascular dysfunction was identified as coronary flow reserve below 2·0 and index of microcirculatory resistance of ≥25. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure. The Multicenter FLOW-CMD Registry study is registered with ClinicalTrials.gov (NCT05369182).
FINDINGS: Between April 22, 2022, and Nov 19, 2024, 5764 patients were screened and 1003 patients were enrolled (756 men and 247 women). Among these patients, coronary microvascular dysfunction was observed in 123 (21·5%) of 573 patients with obstructive epicardial coronary artery disease and in 40 (9·3%) of 430 patients without obstructive epicardial coronary artery disease. At a median follow-up of 1·9 years, the primary endpoint occurred in 26 patients (2-year Kaplan-Meier estimate 18·8%) with coronary microvascular dysfunction and 70 patients (2-year Kaplan-Meier estimate 10·5%) with preserved microvascular function (hazard ratio 1·91 [95% CI 1·22-2·99]; p=0·0047).
INTERPRETATION: In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction coexisted with epicardial coronary artery disease and was associated with a higher risk of the composite of all-cause death, myocardial infarction, clinically driven repeat revascularisation, or hospitalisation for heart failure.
FUNDING: Abbott Vascular and Boston Scientific.